

13 March 2019

To: Recipients of M100, 29th ed.

From: Jennifer K. Adams, MT(ASCP), MSHA  
Vice President, Standards and Quality

Subject: Daptomycin Breakpoint Revision

This notice is intended to inform users of a clinically important revision made to daptomycin breakpoints for *Enterococcus* spp. published in CLSI document M100, *Performance Standards for Antimicrobial Susceptibility Testing*, 29th ed.

During the 27-29 January 2019 meeting of the CLSI Subcommittee on Antimicrobial Susceptibility Testing, data were presented that warranted the approval of separate daptomycin breakpoints for *Enterococcus faecium* only and *Enterococcus* spp. (other than *E. faecium*). These revisions have been made in all electronic versions of M100, 29th ed. In addition, this memo has been provided to customers who have already received print copies and will be included with all print versions going forward. These revisions will be published in CLSI document M100, 30th ed.

Excerpts from Table 2D are included below. The first excerpt shows the daptomycin breakpoints as they were originally published in the 29th edition. The second excerpt shows the revised daptomycin breakpoints as they will be published in the upcoming 30th edition.

Updates to reflect these revisions were also made in the following locations:

- Overview of Changes
- CLSI Breakpoint Additions/Revisions Since 2010
- Appendix E

**Table 2D. Zone Diameter and MIC Breakpoints for *Enterococcus* spp. (as originally published in 29th ed.)**

The daptomycin breakpoints and associated comments for *Enterococcus* spp. as originally published in the 29th edition are shown in the Table 2D excerpt below.

Test/Report Group	Antimicrobial Agent	Disk Content	Interpretive Categories and Zone Diameter Breakpoints, nearest whole mm			Interpretive Categories and MIC Breakpoints, µg/mL				Comments
			S	I	R	S	SDD	I	R	
<b>LIPOPEPTIDES</b>										
B	Daptomycin	-	-	-	-	≤ 1	2-4	-	≥ 8	<p>(11) Daptomycin should not be reported for isolates from the respiratory tract.</p> <p>(12) The breakpoint for susceptible is based on a dosage regimen of 6 mg/kg per day in adults.</p> <p>(13) The breakpoint for SDD is based on a dosage regimen of 8-12 mg/kg per day in adults and is intended for serious infections due to <i>Enterococcus</i> spp. Consultation with an infectious diseases specialist is recommended.</p>

Table 2D. Zone Diameter and MIC Breakpoints for *Enterococcus* spp. (revised, to be published in upcoming 30th ed.)

The revised daptomycin breakpoints and associated comments are shown in the revised Table 2D excerpt below. All revisions are highlighted.

Test/Report Group	Antimicrobial Agent	Disk Content	Interpretive Categories and Zone Diameter Breakpoints, nearest whole mm			Interpretive Categories and MIC Breakpoints, µg/mL				Comments
			S	I	R	S	SDD	I	R	
<b>LIPOPEPTIDES</b>										
B	Daptomycin <i>E. faecium</i> only	-	-	-	-	-	≤ 4	-	≥ 8	<p>(11) Daptomycin should not be reported for isolates from the respiratory tract.</p> <p>(12) The breakpoint for SDD is based on a dosage regimen of 8-12 mg/kg administered every 24 h in adults and is intended for serious infections due to <i>E. faecium</i>. Consultation with an infectious diseases specialist is recommended.</p>
B	Daptomycin <i>Enterococcus</i> spp. (other than <i>E. faecium</i> )	-	-	-	-	≤ 2	-	4	≥ 8	<p>(13) The breakpoint for susceptible is based on a dosage regimen of 6 mg/kg administered every 24 h in adults.</p> <p>See comment (11).</p>

If you require any additional clarification regarding these revisions, please contact CLSI Customer Service ([customerservice@clsi.org](mailto:customerservice@clsi.org)).

We appreciate your commitment to CLSI and regret any inconvenience.